With the rapid increase in the use of BTK inhibitors managing CV risk is increasingly challenging and important. In this episode leading experts from the University of Pennsylvania medical school guide us through some of these complexities. Watch to the full webinar here: https://www.radcliffecardiology.com/webinars/managing-cv-risk-patients-cll
Dr. Emily Tomasulo is a Hematologist/Oncologist who specializes in B-cell lymphoma and cellular therapy at Pennsylvania Hospital and the Hospital of the University of Pennsylvania. She sits on ECOG-ACRIN Leukemia Committee and her research and clinical interests focus on the use of targeted and cellular therapies in B-cell malignancies with particular attention to cardiovascular adverse effects.
Dr. Michael Fradley is an Associate Professor of Clinical Medicine in the Division of Cardiology at the Perelman School of Medicine at the University of Pennsylvania and Medical Director of the Thalheimer Center for Cardio-Oncology. He trained at Yale University, Johns Hopkins University, and Massachusetts General Hospital. His clinical and research interests focus on arrhythmic complications of cancer therapies. He currently serves as President of the International Cardio-Oncology Society (IC-OS).